Discovery Labs Sees Filing Surfaxin Response With FDA In 3Q
10 Januar 2011 - 2:50PM
Dow Jones News
Discovery Laboratories Inc. (DSCOD) said it could be able to
file a complete response with the U.S. Food and Drug Administration
early in the third quarter on Surfaxin, its experimental
preventative drug for respiratory distress syndrome in premature
infants.
The drug developer, which had said in June the filing was on
track for the first quarter, now says it has had multiple
discussions with the agency regarding tests on the drug.
Like many drug developers, Discovery Labs has been unprofitable
as it generates no revenue. It enacted a 1-for-15 reverse stock
split last month in order to keep its Nasdaq listing and earlier
this year sold stock and warrants, seeking proceeds for research
and development.
Shares were down 1.9% at $3.63 in premarket activity.
-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240;
matthew.jarzemsky@dowjones.com
Discovery Laboratories, Inc. (MM) (NASDAQ:DSCOD)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Discovery Laboratories, Inc. (MM) (NASDAQ:DSCOD)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Discovery Laboratories, Inc. (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Discovery Laboratories Inc. News-Artikel